Leukemia & Lymphoma
Volume 61, 2020 - Issue 3
Original Articles
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Maria-Victoria MateosHaematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain; 
http://orcid.org/0000-0003-2390-1218View further author information
http://orcid.org/0000-0003-2390-1218View further author information, Jesus San-MiguelClínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain; http://orcid.org/0000-0002-9183-4857View further author information
http://orcid.org/0000-0002-9183-4857View further author information, Hartmut GoldschmidtInternal Medicine V and National Center of Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany; http://orcid.org/0000-0003-0961-0035View further author information
http://orcid.org/0000-0003-0961-0035View further author information, Pieter SonneveldDepartment of Haematology, Erasmus MC, Rotterdam, The Netherlands; http://orcid.org/0000-0002-0808-2237View further author information
http://orcid.org/0000-0002-0808-2237View further author information, Meletios A. DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; http://orcid.org/0000-0001-8990-3254View further author information
http://orcid.org/0000-0001-8990-3254View further author information, Bart HeegIngress Health, Rotterdam, The Netherlands; http://orcid.org/0000-0002-9226-3232View further author information
http://orcid.org/0000-0002-9226-3232View further author information, Mahmoud HashimIngress Health, Rotterdam, The Netherlands; http://orcid.org/0000-0002-5775-9590View further author information
http://orcid.org/0000-0002-5775-9590View further author information, William DeraedtOncology R&D, Janssen Research & Development, Beerse, Belgium; http://orcid.org/0000-0003-1414-2387View further author information
http://orcid.org/0000-0003-1414-2387View further author information, Peter HuStatistical Programming (Haematology), Janssen Research & Development, LLC, Raritan, NJ, USA; http://orcid.org/0000-0002-4061-8484View further author information
http://orcid.org/0000-0002-4061-8484View further author information, Annette LamGlobal Market Access and Health Policy, Janssen Global Services, LLC, Raritan, NJ, USAhttp://orcid.org/0000-0003-2037-3464View further author information
http://orcid.org/0000-0003-2037-3464View further author information & Jianming HeGlobal Market Access and Health Policy, Janssen Global Services, LLC, Raritan, NJ, USACorrespondence[email protected]
http://orcid.org/0000-0002-5015-3713View further author information
http://orcid.org/0000-0002-5015-3713View further author information show all